MedPal AI is an AIM-quoted digital health and pharmacy group combining AI-driven health tools with regulated prescription dispensing. It operates NHS distance selling pharmacy hubs, an online pharmacy brand, a weight management clinic and care home pharmacy services. The 10.94% decline on 20 October, …
RUA Life Sciences is a medical device contract development and manufacturing organisation specialising in implantable textiles and the Elast-Eon biostable polymer. It also licenses its polymer technology to device makers. The 9.90% decline on 20 October, 2026 follows a substantial rise in the shares …
Ondine Biomedical develops photodisinfection therapies that use light-activated agents to kill pathogens. Its Steriwave nasal treatment aims to reduce infections in surgical patients.
Bioventix develops and supplies sheep monoclonal antibodies used in blood tests run on large automated analysers in hospital and clinical laboratories. Its customers are major diagnostic companies that pay royalties on test sales.
Creo Medical Group Plc (LSE:CREO) is relevant to investors tracking UK-listed shares because its valuation depends on a combination of company execution, sector conditions and the market’s expectations for future cash generation. The most useful way to assess the stock on 20 October 2026 …
Shield Therapeutics Plc (LSE:STX) is relevant to investors tracking UK-listed shares because its valuation depends on a combination of company execution, sector conditions and the market’s expectations for future cash generation. The most useful way to assess the stock on 20 October 2026 is …
Expected first-half revenue is approximately £96 million; annualised new business wins reached £10.6 million and net debt excluding leases declined to £70.4 million.
The company issued a trading update on 20 October; precise financial figures require confirmation from the full statement.
The company announced the result of a fundraise and restoration of trading on 20 October; the final issuance terms and share count merit checking.
The company recently disclosed a £119,000 modelling contract and exploration of additional commercial opportunities.